Pierre Fabre and Y-Biologics are jointly researching new immunotherapies based on monoclonal antibodies

▴ Pierre Fabre and Y-Biologics are jointly researching new immunotherapies based on monoclonal antibodies
The two partners want to pool their expertise in order to identify and develop new monoclonal antibodies for cancer therapy

South Korean biotechnology company Y-Biologics and French pharmaceutical company Pierre Fabre are planning a strategic partnership to explore cancer immunotherapies. The announcement took the form of a written letter of intent signed by both parties. The decision is to be sealed with a detailed agreement in the coming months. The cooperation is planned for three years, with the option of an extension for a further two years.

Y-Biologics specializes in monoclonal antibody research. The Pierre Fabre Group is the second-largest pharmaceutical laboratory in France. The two partners want to pool their expertise in order to identify and develop new monoclonal antibodies for cancer therapy that target central immunosuppressive mechanisms in solid tumors.

It has been found that in the microenvironment of such growths there are important cellular components that help the tumour suppress the body's immune response. This is where immunotherapies for cancer come in: They reactivate the immune system in a targeted manner so that it can destroy the tumour cells. The partnership between Pierre Fabre and Y-Biologics aims to provide patients with novel forms of therapy. The basis for this is formed by monoclonal antibodies designed for therapy. With this, the researchers want to reprogram some cell types so that they stimulate and/or restore the immune system's defense reactions against the tumour.

The collaboration provides for Y-Biologics to manufacture monoclonal antibodies for therapy and diagnosis on the basis of its display platforms for human antibodies - for central molecular building blocks that Pierre Fabre has previously identified. Pierre Fabre brings his expertise in the field of cancer immunotherapy with him. The company wants to strengthen its teams in the Pierre Fabre Immunology Center (CIPF) in Saint-JulienMake full use of en-Genevois: the identification and evaluation of targets that suppress the immune system, as well as targeted immunotherapy.

In addition, the Pierre Fabre R&D Center at the Oncopole campus in Toulouse will contribute to success with its expertise in the fields of translational medicine, pharmacology, toxicology, and clinical development.

These Young Woo Park , President, and CEO of Y-Biologics: "We are very pleased that we can participate in the joint study and the optional license agreement to the by Pierre Fabre to explore proposed new targets for cancer immunotherapy antibodies - using the display Platform for human antibodies from Y-Biologics. Pierre Fabre is an important authority in the field of oncology. We are very proud that the group trusts our platform in their antibody research and thereby helps us to spread our technology worldwide. We hope that the candidates discovered by Y-Biologics will be with Pierre Fabreadvance into the preclinical and clinical phases. This partnership also gives us opportunities for further joint developments. It's nice that we can continue to work closely with Pierre Fabre on this project. "

“Our main strategic focus is on innovations for oncology. We are all the more looking forward to discovering and developing the new generation of monoclonal antibodies together with Y-Biologics. The agreement with Y-Biologics shows how much Pierre Fabre is committed to finding innovative therapies as quickly as possible for patients who do not respond to the current treatments or who reject them, " adds Jean-Luc Lowinski, who works at Pierre Fabre Medical Care Business Unit heads.

With this partnership, Pierre Fabre has the opportunity to acquire all rights to the antibodies that arise in the course of the collaboration. However, Y-Biologics may be entitled to financial compensation for research costs incurred, bonus payments for milestones achieved, and profit-sharing.

Tags : #PierreFabre #LatestNewsonPierreFabre24thNov #Y-Biologics #LatestNewsonY-Biologics24thNov #LatestPharmaCollaboration24thNov #LatestPharmaNews24thNov #LatestNewsonCancerTherapy24thNov #France #SouthKorea #CancerImmunotherapy

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024